The Place of protease inhibitors in antiretroviral treatment.

Article Details

Citation

Copy to clipboard

Tenore SB, Ferreira PR

The Place of protease inhibitors in antiretroviral treatment.

Braz J Infect Dis. 2009 Oct;13(5):371-4. doi: 10.1590/S1413-86702009000500012.

PubMed ID

20428639 [ View in PubMed

]

Abstract

With the introduction of highly active antiretroviral therapy, a number of drugs have been developed. The best choice concerning which antiretroviral analogs to start is always under discussion, especially in the choice between non-nucleoside reverse transcriptase inhibitors-based therapies and ritonavir-boosted protease inhibitors. Both are proven to control viral replication and lead to immunological gain. The choice between a non-nucleoside analog reverse transcriptase inhibitor and a protease inhibitor as a third antiretroviral drug in the therapy should consider factors related to the individual, as well as the inclusion of the best therapy in the patient's daily activities and potential adherence. The protease inhibitor-based therapies showed similar efficacy among the various inhibitors with characteristics concerning the adverse events from each medicine. For the treatment of protease-resistant patients, darunavir and tipranavir showed good efficacy with higher genetic barrier to resistance.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tipranavir	Human immunodeficiency virus type 1 protease	Protein	Human immunodeficiency virus 1	Yes	Inhibitor	Details